EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

Lana A Castellucci, Vivien M Chen, Michael J Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn iD, Benoit Côté, Sam Schulman iD, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan und 21 weitere

New England Journal of Medicine · 12.03.2026 · 394 (11) · 1051-1060

DOI: 10.1056/nejmoa2510703 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift New England Journal of Medicine, erschienen am 12.03.2026. Verfasst von Lana A Castellucci und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa. Hauptthemen laut MEDLINE: Anticoagulants, Factor Xa Inhibitors, Hemorrhage, Pulmonary Embolism. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: CIHR, National Health and Medical Research Council, Institute of Circulatory and Respiratory Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two medications. METHODS: In an international trial with a prospective, randomized, open-label, blinded end-point design, we assigned, in a 1:1 ratio, eligible patients with acute symptomatic pulmonary embolism or proximal deep-vein thrombosis to receive apixaban or rivaroxaban for 3 months. Apixaban was given at a dose of 10 mg twice daily for 7 days followed by 5 mg twice daily, and rivaroxaban was given at a dose of 15 mg twice daily for 21 days followed by 20 mg daily. The primary outcome was clinically relevant bleeding, a composite of major bleeding or clinically relevant nonmajor bleeding, as defined according to the International Society on Thrombosis and Haemostasis, during the 3-month trial period. Secondary outcomes included death from any cause. RESULTS: A total of 2760 patients underwent randomization: 1370 to the apixaban group and 1390 to the rivaroxaban group. A primary-outcome event occurred in 44 of 1345 patients (3.3%) in the apixaban group and 96 of 1355 patients (7.1%) in the rivaroxaban group (relative risk, 0.46; 95% confidence interval [CI], 0.33 to 0.65; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsFactor Xa InhibitorsHemorrhagePulmonary EmbolismRivaroxabanVenous ThromboembolismVenous ThrombosisAdultAgedFemaleHumansMaleMiddle AgedAcute DiseaseProspective StudiesPyrazolesPyridonesRiskDrug Administration ScheduleIncidence

Substanzen

AnticoagulantsapixabanFactor Xa InhibitorsPyrazolesPyridonesRivaroxaban

Autor:innen und Institutionen

  • Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa.
  • Department of Haematology and Australian and New Zealand Army Corps Research Institute, Concord Repatriation and General Hospital, Sydney.
  • Sydney Concord Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney.
  • National Health and Medical Research Council Clinical Trials Centre, Sydney.
  • Department of Medicine, Division of Hematology, Western University, London, ON, Canada.
  • Ottawa Methods Centre, Ottawa Hospital Research Institute, Ottawa.

ORCID-Profile: Susan Kahn, Sam Schulman, Huyen A Tran, Tobias Tritschler, Lisa Baumann Kreuziger

Förderung

  • CIHR
  • National Health and Medical Research Council
  • Institute of Circulatory and Respiratory Health
  • the International Network of Venous Thromboembolism Clinical Research Networks

Zitieren

APA

Castellucci, L. A., Chen, V. M., Kovacs, M. J., Lazo-Langner, A., Greenstreet, P., Kahn, S., Côté, B., Schulman, S., de Wit, K., Douketis, J., Suryanarayan, D., Wan, T., Yeo, E., Le Templier, G., Tran, H. A., Willcox, A., Crowther, H. J., Prasad, R., Shivakumar, S., …, & COBRRA Trial Investigators (2026). Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism. New England Journal of Medicine, 394(11), 1051-1060. https://doi.org/10.1056/nejmoa2510703

Vancouver

Castellucci LA, Chen VM, Kovacs MJ, Lazo-Langner A, Greenstreet P, Kahn S, et al. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism. New England Journal of Medicine. 2026;394(11):1051-1060. doi:10.1056/nejmoa2510703

BibTeX
@article{Castellucci2026,
  author = {Castellucci, Lana A and Chen, Vivien M and Kovacs, Michael J and Lazo-Langner, Alejandro and Greenstreet, Peter and Kahn, Susan and Côté, Benoit and Schulman, Sam and de Wit, Kerstin and Douketis, James and Suryanarayan, Deepa and Wan, Tony and Yeo, Erik and Le Templier, Genevieve and Tran, Huyen A and Willcox, Abbey and Crowther, Helen J and Prasad, Ritam and Shivakumar, Sudeep and Umana, Etimbuk and Ni Ainle, Fionnuala and Tritschler, Tobias and Barco, Stefano and Galanaud, Jean-Philippe and Blondon, Marc and Baumann Kreuziger, Lisa and Solymoss, Susan and Kearon, Clive and Thomas, Erin and Ramsay, Tim and Le Gal, Gregoire and Rodger, Marc and COBRRA Trial Investigators, COBRRA Trial Investigators},
  title = {Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {11},
  pages = {1051--1060},
  doi = {10.1056/nejmoa2510703}
}
Kostenlos starten →